About the Georgetown University Lombardi Center for Cancer Drug Discovery

The GULCCDD is poised to support multidisciplinary projects. Our senior team members have significant experience and expertise with various risk-mitigation strategies, implementing alternative approaches to solve challenges, and advancing small molecule drug discovery projects. Through the Georgetown Lombardi Comprehensive Cancer Center team collaboration, our center — computational chemists, structural biologists, cancer chemical biologists, and molecular oncologists — focus on identifying and developing novel cancer drugs targeting a wide variety of biological targets, including high-risk targets not yet pursued by the commercial sector.

Notably, the cancer drug discovery projects often deal with novel, undruggable or untraditional targets that our center may play a significant but distinguished role with unique assets that can be quickly tuned or optimized for drug discovery projects. Such flexible activities would allow drug candidates to be rapidly validated and moved into the candidate selection phase, maximizing the opportunity and mitigating the death-valley scenario in the translational drug discovery pipeline.

The GULCCDD is home to multiple SBIR and STTR grants on which GU PIs are the academic leads. These include some in which the company is a Georgetown University spin-off. The center management and governance structure are designed to efficiently conduct drug discovery research as a team in a communicative, collaborative, and productive manner.

We have deep experience in efficiently managing and implementing process team logistics for external contractual mechanisms. Our investigators have had proven translational success with contractually sponsored, service, and collaborative research projects with numerous oncology drug discovery companies academic and government institutions.

Our strong team science activities include operating Georgetown Lombardi shared resources, with numerous publications and patent applications related to oncology therapeutics.